Business Context and Reporting Period
Company: Capricor Therapeutics, Inc. (CAPR)
Filing Type: Form 8-K (Current Report)
Report Date: March 12, 2026
Reporting Period: Fourth Quarter and Full Year ended December 31, 2025
The filing serves as a notification that the Company issued a press release announcing its financial results for the specified period. The detailed financial data is contained in Exhibit 99.1, which is furnished but not deemed filed for liability purposes under Section 18 of the Exchange Act.
Key Financial Metrics
Revenue, Profit, Cash Flow, Margins, Debt, and Liquidity: The provided text does not contain specific numerical values for revenue, net income, operating cash flow, margins, debt levels, or liquidity positions. These figures are referenced as being included in the attached press release (Exhibit 99.1) but are not present in the body of this Form 8-K.
Material Changes
Comparison to Prior Period: The filing text does not provide specific data points to compare current performance against prior comparable periods. It only confirms the announcement of results for Q4 and Full Year 2025.
Guidance, Outlook, and Risks
Management Commentary and Outlook: The filing references a "Corporate Update" within the attached press release, but the specific content regarding future guidance, strategic outlook, or management commentary is not detailed in this document.
Risks and Contingencies: No specific risks, contingencies, or unusual items are described in the text of this Form 8-K.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual financial figures (Revenue, Net Loss, Cash Position).
- Verify the specific details of the "Corporate Update" mentioned in the press release title.
- Confirm the Company's cash runway and burn rate based on the full year 2025 results.
- Check for any updates on clinical trial progress or regulatory milestones included in the press release.